- Home
- AIO vs GHRS Comparison
AIO vs GHRS Comparison
Compare AIO & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIO
- GHRS
- Stock Information
- Founded
- AIO 2019
- GHRS 2018
- Country
- AIO United States
- GHRS Ireland
- Employees
- AIO N/A
- GHRS N/A
- Industry
- AIO Finance/Investors Services
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- AIO Finance
- GHRS Health Care
- Exchange
- AIO Nasdaq
- GHRS Nasdaq
- Market Cap
- AIO 808.3M
- GHRS 892.0M
- IPO Year
- AIO N/A
- GHRS 2021
- Fundamental
- Price
- AIO $22.16
- GHRS $14.38
- Analyst Decision
- AIO
- GHRS Strong Buy
- Analyst Count
- AIO 0
- GHRS 9
- Target Price
- AIO N/A
- GHRS $30.11
- AVG Volume (30 Days)
- AIO 141.5K
- GHRS 407.8K
- Earning Date
- AIO 01-01-0001
- GHRS 11-06-2025
- Dividend Yield
- AIO 9.05%
- GHRS N/A
- EPS Growth
- AIO N/A
- GHRS N/A
- EPS
- AIO N/A
- GHRS N/A
- Revenue
- AIO N/A
- GHRS N/A
- Revenue This Year
- AIO N/A
- GHRS N/A
- Revenue Next Year
- AIO N/A
- GHRS N/A
- P/E Ratio
- AIO N/A
- GHRS N/A
- Revenue Growth
- AIO N/A
- GHRS N/A
- 52 Week Low
- AIO $15.09
- GHRS $6.72
- 52 Week High
- AIO $20.25
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- AIO 33.82
- GHRS 55.96
- Support Level
- AIO $21.46
- GHRS $13.71
- Resistance Level
- AIO $23.15
- GHRS $15.01
- Average True Range (ATR)
- AIO 0.54
- GHRS 0.98
- MACD
- AIO -0.21
- GHRS 0.04
- Stochastic Oscillator
- AIO 24.71
- GHRS 74.17
About AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.